Indian biotech startup PopVax has unveiled a research, development and manufacturing facility in Hyderabad dedicated to RNA medicines, including personalized cancer vaccines. The company said the facility is intended to support treatments designed around an individual patient’s biological, genetic or disease characteristics.
PopVax, which was launched in 2021, called the facility the RNA Foundry. The company said it plans to make more than 100 personalized cancer vaccines during the next 12 months and is asking people to submit their cancer type, stage and sequencing information for case-by-case development.
A platform for individualized drug development
The facility uses PopVax’s proprietary messenger RNA platform and a lipid nanoparticle formulation that the company describes as fridge-stable. PopVax said the site was built to align with global Good Manufacturing Practices, a set of production standards used for medicines.
| Company | Facility | Location | Stated focus |
|---|---|---|---|
| PopVax | RNA Foundry | Hyderabad, India | RNA research, development and manufacturing |
Messenger RNA medicines work by instructing cells to produce a protein that can train the immune system. PopVax contrasted its approach with conventional vaccines, which are generally developed in standardized forms for broader populations. Its stated goal is to make the same underlying platform available for customized products.
“Personalised RNA cancer vaccines have the potential to transform cancer care. But research, development, and manufacturing for these medicines is not widely available to those that need them the most. Over the last four years at PopVax, we've learned that making RNA medicines to a high standard of quality is not easy,” said Soham Sankaran, founder of PopVax.
The RNA Foundry is also the facility where PopVax said it manufactured its first mRNA vaccine candidate. That candidate entered clinical trials in Australia in August, according to the company. The announcement did not provide clinical findings for that candidate or evidence that the personalized cancer vaccines planned at the facility are effective in patients.
Manufacturing capacity comes before clinical validation
PopVax’s announcement centers on its manufacturing capability and its intention to produce individualized vaccine candidates, rather than on a regulatory approval or trial result. Personalized cancer vaccines typically require information about a patient’s tumor or disease biology before a candidate can be designed, but the company’s announcement did not disclose development timelines, regulatory status, pricing or the clinical protocols for the planned vaccines.
The company’s stated commitment to produce more than 100 vaccines in 12 months represents an operational target, not a measure of patient benefit. Any eventual use in medical care would depend on the development, testing and regulatory review required for the relevant products. For now, PopVax is presenting the RNA Foundry as infrastructure intended to make individualized RNA medicine development and manufacturing available in India.
